Michaelx Repka News Today : Breaking News, Live Updates & Top Stories | Vimarsana

But docs aren't ready to ditch the treatment, which is commonly used in Asia

A study conducted at Vanderbilt University Medical Center and 11 other hospitals and practices across the United States shows that use of low-dose atropine eyedrops, commonly used in a higher dose to treat lazy eye, was no better than a placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years.

Findings seen in children aged 5 to 12 years with low-to-moderate bilateral myopia.

Use of atropine, 0.01%, eye drops did not slow myopia progression or axial elongation better than placebo in children aged 5 - 12 years.

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, according to a randomized controlled trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the National Eye Institute (NEI). The trial aimed to identify an effective way to manage this leading and increasingly common cause of refractive error, which can cause serious uncorrectable vision loss later in life. Results from the trial were published in JAMA Ophthalmology.